• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.比较清髓性预处理与降低毒性预处理和脐血移植在儿科受者中免疫重建和移植物抗宿主病的情况。
Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.
2
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.成人患者接受氟达拉滨和马法兰预处理后行haploidentical 与haplo-cord 移植的比较。
Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.
3
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.一种新的预处理方案可显著促进移植后免疫重建,改善脐血移植患者的预后。
Stem Cells Dev. 2019 Oct 15;28(20):1376-1383. doi: 10.1089/scd.2019.0139. Epub 2019 Sep 26.
4
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.日本儿童和青少年急性髓系白血病中,氟达拉滨与马法兰联合的低毒性预处理方案与放疗和/或白消安的清髓性预处理方案的比较。
Pediatr Blood Cancer. 2015 May;62(5):883-9. doi: 10.1002/pbc.25389. Epub 2014 Dec 24.
5
In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.在干细胞移植中,通过限制移植物抗宿主病的发病率,对清髓性预处理的耐受性得到改善。
Biol Blood Marrow Transplant. 2008 Jun;14(6):709-18. doi: 10.1016/j.bbmt.2008.01.007.
6
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.在现代时代,异体干细胞移植中氟达拉滨/白消安与环磷酰胺/全身照射的清髓性调理方案比较:队列分析。
Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16.
7
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.马利兰、氟达拉滨和阿仑单抗作为降低毒性方案用于治疗儿童恶性和非恶性疾病可改善植入和移植物抗宿主病,而不延迟免疫重建。
Biol Blood Marrow Transplant. 2012 Nov;18(11):1656-63. doi: 10.1016/j.bbmt.2012.05.006. Epub 2012 May 15.
8
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.比较使用他克莫司预防移植物抗宿主病的清髓性和减低强度预处理非亲缘供者异基因外周血造血干细胞移植治疗 AML 的结果。
Ann Hematol. 2021 Apr;100(4):969-978. doi: 10.1007/s00277-021-04445-8. Epub 2021 Feb 16.
9
Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.异基因无关脐血移植治疗儿童噬血细胞性淋巴组织细胞增生症的持久嵌合状态和长期生存:单中心经验。
Biol Blood Marrow Transplant. 2017 Oct;23(10):1722-1728. doi: 10.1016/j.bbmt.2017.06.013. Epub 2017 Jun 21.
10
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.在成年人血液恶性肿瘤患者中,使用抗胸腺球蛋白和清髓性预处理进行单份脐带血移植后的免疫重建。
Ann Hematol. 2024 Jul;103(7):2475-2484. doi: 10.1007/s00277-024-05758-0. Epub 2024 Apr 18.

引用本文的文献

1
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.同种异体移植治疗镰状细胞病中的供者嵌合体和免疫重建。
Front Immunol. 2022 Dec 9;13:1055497. doi: 10.3389/fimmu.2022.1055497. eCollection 2022.
2
Natural killer cells 5616 have higher counts in the umbilical cord blood than in the adult peripheral blood.自然杀伤细胞5616在脐带血中的数量高于成人外周血中的数量。
Hematol Transfus Cell Ther. 2023 Oct-Dec;45(4):419-427. doi: 10.1016/j.htct.2022.07.001. Epub 2022 Aug 19.
3
Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside.胱氨酸病的造血干细胞基因治疗:从基础到临床。
Cells. 2021 Nov 23;10(12):3273. doi: 10.3390/cells10123273.
4
Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.比较非亲缘单份脐带血与“体外”T 细胞去除的单倍体相合移植治疗血液系统恶性肿瘤患儿的临床结局。
World J Pediatr. 2021 Dec;17(6):609-618. doi: 10.1007/s12519-021-00461-w. Epub 2021 Sep 30.
5
Different Immune Reconstitution between Cord Blood and Unrelated Bone Marrow Transplantation with Relation to Chronic Graft-versus-Host Disease.脐血与非亲缘骨髓移植在慢性移植物抗宿主病方面的不同免疫重建
Int J Hematol Oncol Stem Cell Res. 2020 Jan 1;14(1):1-10.
6
Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation.免疫生物学在脐带血移植中的临床相关性
J Clin Med. 2019 Nov 14;8(11):1968. doi: 10.3390/jcm8111968.
7
Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56 NK cells.人类脐血与外周血 CD56NK 细胞的免疫表型、细胞毒性、蛋白质组学和基因组学特征。
Innate Immun. 2019 Jul;25(5):294-304. doi: 10.1177/1753425919846584. Epub 2019 May 8.
8
Cord Blood Banking for Potential Future Transplantation.用于未来潜在移植的脐带血储存
Pediatrics. 2017 Nov;140(5). doi: 10.1542/peds.2017-2695.
9
Engineering cord blood to improve engraftment after cord blood transplant.改造脐带血以改善脐带血移植后的植入情况。
Stem Cell Investig. 2017 May 25;4:41. doi: 10.21037/sci.2017.05.01. eCollection 2017.
10
Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.实现从脐带血快速产生靶向BK病毒、腺病毒、巨细胞病毒和EB病毒的多病毒特异性T细胞。
Mol Ther Methods Clin Dev. 2017 Mar 8;5:13-21. doi: 10.1016/j.omtm.2017.02.001. eCollection 2017 Jun 16.

本文引用的文献

1
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.第六至第八个十年患有急性髓系白血病或骨髓增生异常综合征的患者采用降低毒性静脉注射马利兰-氟达拉滨和异基因造血干细胞移植。
Biol Blood Marrow Transplant. 2011 Oct;17(10):1490-6. doi: 10.1016/j.bbmt.2011.02.007. Epub 2011 Feb 18.
2
Cord blood transplantation and stem cell regenerative potential.脐带血移植与干细胞再生潜能。
Exp Hematol. 2011 Apr;39(4):393-412. doi: 10.1016/j.exphem.2011.01.002. Epub 2011 Jan 13.
3
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.脐带血移植后预处理方案强度对急性髓系白血病疗效的影响。
Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34. doi: 10.1016/j.bbmt.2011.01.007. Epub 2011 Jan 11.
4
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.BU、氟达拉滨和阿仑单抗预处理降低儿童和青少年异基因造血干细胞移植毒性的初步研究。
Bone Marrow Transplant. 2011 Jun;46(6):790-9. doi: 10.1038/bmt.2010.209. Epub 2010 Sep 6.
5
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.体内阿仑单抗剂量对减低强度预处理和 HLA 同胞干细胞移植的影响:药代动力学、移植物抗宿主病和免疫重建。
Blood. 2010 Oct 21;116(16):3080-8. doi: 10.1182/blood-2010-05-286856. Epub 2010 Jun 29.
6
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.从脐血和外周血中通过单一培养获得具有抗病毒和抗白血病特异性的人 T 淋巴细胞,以防止干细胞移植后感染和复发。
Blood. 2010 Apr 1;115(13):2695-703. doi: 10.1182/blood-2009-09-242263. Epub 2010 Jan 28.
7
Unrelated umbilical cord blood transplantation and immune reconstitution.无关脐带血移植与免疫重建。
Semin Hematol. 2010 Jan;47(1):22-36. doi: 10.1053/j.seminhematol.2009.10.009.
8
Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.1061 例血液系统恶性肿瘤患者的总核细胞剂量和 HLA 配型对移植结果的联合影响。
Blood. 2010 Mar 4;115(9):1843-9. doi: 10.1182/blood-2009-07-231068. Epub 2009 Dec 22.
9
Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.基于白消安的减低强度与清髓性预处理在儿科异基因造血干细胞移植受者中病毒和真菌感染的发生率。
Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30.
10
An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.儿童异基因造血干细胞移植受者中静脉和口服吗替麦考酚酯联合他克莫司预防移植物抗宿主病的年龄依赖性药代动力学研究。
Biol Blood Marrow Transplant. 2010 Mar;16(3):333-43. doi: 10.1016/j.bbmt.2009.10.007. Epub 2009 Oct 14.

比较清髓性预处理与降低毒性预处理和脐血移植在儿科受者中免疫重建和移植物抗宿主病的情况。

A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

机构信息

Department of Pediatrics, NewYork-Presbyterian Morgan Stanley Children's Hospital, Columbia University, New York, NY, USA.

出版信息

Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.

DOI:10.1111/j.1365-2141.2011.08822.x
PMID:21848882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3188698/
Abstract

Immune reconstitution appears to be delayed following myeloablative conditioning (MAC) and umbilical cord blood transplantation (UCBT) in paediatric recipients. Although reduced toxicity conditioning (RTC) versus MAC prior to allogeneic stem cell transplantation is associated with decreased transplant-related mortality, the effects of RTC versus MAC prior to UCBT on immune reconstitution and risk of graft-versus-host disease (GVHD) are unknown. In 88 consecutive paediatric recipients of UCBT, we assessed immune cell recovery and immunoglobulin reconstitution at days +100, 180 and 365 and analysed risk factors associated with acute and chronic GVHD. Immune cell subset recovery, immunoglobulin reconstitution, and the incidence of opportunistic infections did not differ significantly between MAC versus RTC groups. In a Cox model, MAC versus RTC recipients had significantly higher risk of grade II-IV acute GVHD [Hazard Ratio (HR) 6·1, P = 0·002] as did recipients of 4/6 vs. 5-6/6 HLA-matched UCBT (HR 3·1, P = 0·03), who also had significantly increased risk of chronic GVHD (HR 18·5, P = 0·04). In multivariate analyses, MAC versus RTC was furthermore associated with significantly increased transplant-related (Odds Ratio 26·8, P = 0·008) and overall mortality (HR = 4·1, P = 0·0001). The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation.

摘要

骨髓清除性预处理(MAC)和脐带血移植(UCBT)后,儿科受者的免疫重建似乎延迟。虽然异基因干细胞移植前采用减轻毒性预处理(RTC)而非 MAC 与降低移植相关死亡率相关,但 RTC 与 MAC 在前 UCBT 中对免疫重建和移植物抗宿主病(GVHD)风险的影响尚不清楚。在 88 例连续接受 UCBT 的儿科受者中,我们在第 100、180 和 365 天评估了免疫细胞恢复和免疫球蛋白重建,并分析了与急性和慢性 GVHD 相关的危险因素。MAC 与 RTC 组之间的免疫细胞亚群恢复、免疫球蛋白重建和机会性感染的发生率没有显著差异。在 Cox 模型中,MAC 与 RTC 受者发生 II-IV 级急性 GVHD 的风险显著更高[风险比(HR)6.1,P = 0.002],4/6 与 5-6/6 HLA 匹配的 UCBT 受者也是如此(HR 3.1,P = 0.03),他们发生慢性 GVHD 的风险也显著增加(HR 18.5,P = 0.04)。在多变量分析中,MAC 与 RTC 还与显著增加的移植相关(优势比 26.8,P = 0.008)和总死亡率(HR = 4.1,P = 0.0001)相关。采用过继性细胞免疫疗法加速 UCBT 后的免疫重建,并预防和治疗机会性感染和恶性复发,值得进一步研究。